During the past decade, Arkansas Cardiology conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 14 clinical trials were completed, i.e. on average, 93.3% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 9 clinical trials were completed. i.e. 128.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Arkansas Cardiology" #1 sponsor was "Abbott Medical Devices" with 8 trials, followed by "Boehringer Ingelheim" with 4 trials sponsored, "Amgen" with 2 trials sponsored, "Milestone Pharmaceuticals Inc." with 2 trials sponsored and "University of Rochester" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Arkansas Cardiology" #1 collaborator was "Medpace, Inc." with 2 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator, "Abbott Medical Devices" with 1 trials as a collaborator, "Biosense Webster, Inc." with 1 trials as a collaborator and "Chiltern International Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Arkansas Cardiology" are "Atrial Fibrillation" (5 trials), "Heart Failure" (5 trials), "Cardiovascular Disease" (3 trials), "Coronary Artery Disease" (2 trials) and "Myocardial Infarction" (2 trials). Many other conditions were trialed in "Arkansas Cardiology" in a lesser frequency.

Most popular intervention types in "Arkansas Cardiology" are "Drug" (15 trials), "Device" (10 trials), "Procedure" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Dabigatran Etexilate 150mg" (2 trials), "Aptar Pharma Nasal Spray Bidose System" (1 trials), "Aspirin" (1 trials) and "Atrioventricular junctional (AVJ) ablation" (1 trials). Other intervention names were less common.

The vast majority of trials in "Arkansas Cardiology" are 29 trials for "All" genders.

Currently, there are NaN active trials in "Arkansas Cardiology". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in Arkansas Cardiology, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Arkansas Cardiology, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 7 trials that are defined as “Not Applicable".